The head of the Gamaleya Center, Alexander Gintsburg, said that the combination of the Russian Sputnik V coronavirus vaccine and AZD1222 drug, developed by the Anglo-Swedish biopharmaceutical company AstraZeneca and the University of Oxford, will give immunity for two years.
On the air of the Russia 24 TV channel, Gunzburg noted that Russian developers had proposed adding a component of their vaccine to AZD1222, making it a two-component one, which would make it possible to raise the strength of the immune system, and as a result, to extend the period of the drug’s protective effect.
Earlier, Oxford University professor Sarah Gilbert said that the coronavirus vaccine developed by Oxford University together with AstraZeneca could have a greater effect in combination with other drugs, including Russia’s Sputnik V.
Then the Gamaleya Center, AstraZeneca, the Russian Direct Investment Fund and the R-Pharm company signed a memorandum of cooperation. Gunzburg called this cooperation beneficial.
The director of the Gamaleya Center previously said that the Sputnik V vaccine would protect against coronavirus for about two years. He recalled that Sputnik V was created on the same platform as the Ebola vaccine, for which there is similar experimental data.